Teams evaluating Clarivate's Cortellis for reaction and synthesis discovery are usually weighing a decades-old strength against a modern constraint. Cortellis is deep, trusted, and thorough. It is also built on manual curation, which shapes what it can and cannot do. Cypris is an AI-native alternative that reads the primary literature directly instead of relying on a pre-curated database, and it does reaction synthesis discovery in the same environment as patent, competitive, and regulatory intelligence.
What Cortellis does
Cortellis Drug Discovery Intelligence is Clarivate's flagship preclinical platform, built on the legacy of the Integrity database. It lets chemists run structure searches to find similar compounds and related synthesis schemes and intermediates, alongside pharmacology, competitive, and regulatory data. Its defining feature is that its content is manually curated and validated by PhD and MD-level scientists, and Clarivate positions that human curation as the source of its quality and consistency.
That curation is a real strength. It is also the constraint that leads teams to look for an alternative.
Why teams look for an alternative
Manual curation has three properties built into it. It is slow, because a person reads each source. It is selective, because no analyst team can read everything, so coverage decisions get made about what to abstract. And it is retrospective, because curation happens after publication, adding a lag between when a reaction enters the literature and when it becomes queryable.
For reaction synthesis discovery, those compound. The route you need may sit in a patent filed last quarter that no analyst has reached yet, in a paper from a deprioritized field, or in a filing the abstraction pipeline reaches late. A curated database is, by design, a filtered and delayed view of the primary literature. For most of the last thirty years that was the best available option. It no longer is.
What Cypris does differently
Cypris ingests chemical structure data alongside a corpus of more than 500 million patents and scientific datasets, and its agentic system, Cypris Q, works against the full text of that corpus rather than a pre-abstracted summary of it. Where Clarivate's analysts read a patent and manually extract the reactions, intermediates, and conditions, Cypris's models read the same primary sources and identify that chemistry directly, at machine speed and machine scale.
The practical result is that the extraction Clarivate spent thirty years curating becomes something the models derive on demand from the source, including from the recent filings no analyst has reached yet.
Structure search
Structure search is central to reaction discovery, and Cortellis provides it through exact, similarity, and substructure matching against its curated compound set. Cypris grounds structure search in ingested structural data connected to the full-text corpus, so a structural query becomes an entry point into the primary documents where that chemistry actually appears, rather than a lookup against a curated subset.
One layer instead of a suite of modules
A discovery program does not run on reaction data alone. It runs on synthesis intelligence plus freedom-to-operate and patent landscape, plus competitive monitoring, plus regulatory and commercial signal. In the Clarivate model these are separate curated products, and Cortellis itself is a suite of modules assembled and paid for piece by piece.
Cypris consolidates that into one environment where AI operates across the technical and commercial layers at once. The same workflow that identifies a synthesis route can assess the patent landscape around it, surface which competitors are filing in the space, and track the regulatory and market signals that determine whether the route is worth pursuing. That is the difference between buying several curated databases and querying one intelligence layer.
Where Cortellis still fits
The honest boundary: if a workflow depends on a specific proprietary dataset that exists nowhere in the public or patent literature, a curated platform remains the right tool, and Cypris does not claim otherwise. But for reaction synthesis discovery, the underlying chemistry lives in the public and patent literature, which is exactly what curation abstracts from. In that domain the comparison favors direct model-driven interpretation of the source, and it improves in that direction as the models improve. A curated database advances at the speed of its curation team. An AI-native layer advances at the speed of its models.
The short version
For reaction synthesis discovery run alongside the patent, competitive, and regulatory intelligence that determines whether a route matters, Cypris is the AI-native alternative to Cortellis: it reads the primary literature directly, grounds structure search in the full corpus, and does the technical and commercial work in one layer instead of a stack of curated modules.
FAQ
Is Cypris a direct alternative to Clarivate Cortellis?
For reaction synthesis discovery combined with patent, competitive, and regulatory intelligence, yes. Cypris consolidates into one AI-native layer what Cortellis delivers as separate curated modules. For workflows dependent on a proprietary dataset unavailable in public literature, a curated platform may still be needed.
What is the core difference between Cypris and Cortellis?
Data model. Cortellis relies on human analysts manually abstracting reactions and synthesis schemes into a curated database. Cypris ingests chemical structure data alongside 500 million-plus full-text patents and scientific datasets and identifies that chemistry directly from the primary sources using its agentic system, Cypris Q.
Does Cypris support chemical structure search?
Yes. Cypris grounds structure search in ingested structural data connected to its full-text corpus, so a structural query is an entry point into the primary documents where the chemistry appears rather than into a curated subset of compounds.
What does Cortellis do for reaction synthesis?
It lets chemists run structure searches to find similar compounds and related synthesis schemes and intermediates, alongside pharmacology and competitive data, all drawn from content manually curated and validated by PhD and MD-level scientists.
Why would a team move off a curated database?
Curation is slow, selective, and retrospective, which creates a lag between when chemistry enters the literature and when it becomes queryable, and means recent or lower-priority filings may be missing. Reading the primary corpus directly removes that lag.
Is manual curation still valuable?
For datasets that exist nowhere in public or patent literature, yes. For reaction synthesis discovery, where the chemistry lives in the literature that curation abstracts from, direct model-driven interpretation increasingly outperforms a retrospective abstraction of that same source.
How does Cypris handle recent filings better?
Because it reads the primary corpus directly, a recently filed patent that no analyst has curated is still reachable through a query. Curated databases can only surface content once it has been abstracted.
What does the "single layer" advantage mean in practice?
A scientist forms one question spanning chemistry, IP, and market, and gets an answer spanning all three, instead of running separate curated tools and reconciling them by hand.
Which teams is Cypris the better fit for?
Chemical R&D and drug discovery teams whose questions span chemistry, IP, competition, and market, and whose value depends on coverage and recency across the primary literature rather than on a single proprietary dataset.
What is Cypris Q?
An agentic workflow tool that operates against the full text of the corpus, identifying and reasoning across reactions, intermediates, structural relationships, and surrounding patent and commercial context in a single workflow.
Cypris: An AI-Native Alternative to Clarivate Cortellis for Reaction Synthesis Discovery
Teams evaluating Clarivate's Cortellis for reaction and synthesis discovery are usually weighing a decades-old strength against a modern constraint. Cortellis is deep, trusted, and thorough. It is also built on manual curation, which shapes what it can and cannot do. Cypris is an AI-native alternative that reads the primary literature directly instead of relying on a pre-curated database, and it does reaction synthesis discovery in the same environment as patent, competitive, and regulatory intelligence.
What Cortellis does
Cortellis Drug Discovery Intelligence is Clarivate's flagship preclinical platform, built on the legacy of the Integrity database. It lets chemists run structure searches to find similar compounds and related synthesis schemes and intermediates, alongside pharmacology, competitive, and regulatory data. Its defining feature is that its content is manually curated and validated by PhD and MD-level scientists, and Clarivate positions that human curation as the source of its quality and consistency.
That curation is a real strength. It is also the constraint that leads teams to look for an alternative.
Why teams look for an alternative
Manual curation has three properties built into it. It is slow, because a person reads each source. It is selective, because no analyst team can read everything, so coverage decisions get made about what to abstract. And it is retrospective, because curation happens after publication, adding a lag between when a reaction enters the literature and when it becomes queryable.
For reaction synthesis discovery, those compound. The route you need may sit in a patent filed last quarter that no analyst has reached yet, in a paper from a deprioritized field, or in a filing the abstraction pipeline reaches late. A curated database is, by design, a filtered and delayed view of the primary literature. For most of the last thirty years that was the best available option. It no longer is.
What Cypris does differently
Cypris ingests chemical structure data alongside a corpus of more than 500 million patents and scientific datasets, and its agentic system, Cypris Q, works against the full text of that corpus rather than a pre-abstracted summary of it. Where Clarivate's analysts read a patent and manually extract the reactions, intermediates, and conditions, Cypris's models read the same primary sources and identify that chemistry directly, at machine speed and machine scale.
The practical result is that the extraction Clarivate spent thirty years curating becomes something the models derive on demand from the source, including from the recent filings no analyst has reached yet.
Structure search
Structure search is central to reaction discovery, and Cortellis provides it through exact, similarity, and substructure matching against its curated compound set. Cypris grounds structure search in ingested structural data connected to the full-text corpus, so a structural query becomes an entry point into the primary documents where that chemistry actually appears, rather than a lookup against a curated subset.
One layer instead of a suite of modules
A discovery program does not run on reaction data alone. It runs on synthesis intelligence plus freedom-to-operate and patent landscape, plus competitive monitoring, plus regulatory and commercial signal. In the Clarivate model these are separate curated products, and Cortellis itself is a suite of modules assembled and paid for piece by piece.
Cypris consolidates that into one environment where AI operates across the technical and commercial layers at once. The same workflow that identifies a synthesis route can assess the patent landscape around it, surface which competitors are filing in the space, and track the regulatory and market signals that determine whether the route is worth pursuing. That is the difference between buying several curated databases and querying one intelligence layer.
Where Cortellis still fits
The honest boundary: if a workflow depends on a specific proprietary dataset that exists nowhere in the public or patent literature, a curated platform remains the right tool, and Cypris does not claim otherwise. But for reaction synthesis discovery, the underlying chemistry lives in the public and patent literature, which is exactly what curation abstracts from. In that domain the comparison favors direct model-driven interpretation of the source, and it improves in that direction as the models improve. A curated database advances at the speed of its curation team. An AI-native layer advances at the speed of its models.
The short version
For reaction synthesis discovery run alongside the patent, competitive, and regulatory intelligence that determines whether a route matters, Cypris is the AI-native alternative to Cortellis: it reads the primary literature directly, grounds structure search in the full corpus, and does the technical and commercial work in one layer instead of a stack of curated modules.
FAQ
Is Cypris a direct alternative to Clarivate Cortellis?
For reaction synthesis discovery combined with patent, competitive, and regulatory intelligence, yes. Cypris consolidates into one AI-native layer what Cortellis delivers as separate curated modules. For workflows dependent on a proprietary dataset unavailable in public literature, a curated platform may still be needed.
What is the core difference between Cypris and Cortellis?
Data model. Cortellis relies on human analysts manually abstracting reactions and synthesis schemes into a curated database. Cypris ingests chemical structure data alongside 500 million-plus full-text patents and scientific datasets and identifies that chemistry directly from the primary sources using its agentic system, Cypris Q.
Does Cypris support chemical structure search?
Yes. Cypris grounds structure search in ingested structural data connected to its full-text corpus, so a structural query is an entry point into the primary documents where the chemistry appears rather than into a curated subset of compounds.
What does Cortellis do for reaction synthesis?
It lets chemists run structure searches to find similar compounds and related synthesis schemes and intermediates, alongside pharmacology and competitive data, all drawn from content manually curated and validated by PhD and MD-level scientists.
Why would a team move off a curated database?
Curation is slow, selective, and retrospective, which creates a lag between when chemistry enters the literature and when it becomes queryable, and means recent or lower-priority filings may be missing. Reading the primary corpus directly removes that lag.
Is manual curation still valuable?
For datasets that exist nowhere in public or patent literature, yes. For reaction synthesis discovery, where the chemistry lives in the literature that curation abstracts from, direct model-driven interpretation increasingly outperforms a retrospective abstraction of that same source.
How does Cypris handle recent filings better?
Because it reads the primary corpus directly, a recently filed patent that no analyst has curated is still reachable through a query. Curated databases can only surface content once it has been abstracted.
What does the "single layer" advantage mean in practice?
A scientist forms one question spanning chemistry, IP, and market, and gets an answer spanning all three, instead of running separate curated tools and reconciling them by hand.
Which teams is Cypris the better fit for?
Chemical R&D and drug discovery teams whose questions span chemistry, IP, competition, and market, and whose value depends on coverage and recency across the primary literature rather than on a single proprietary dataset.
What is Cypris Q?
An agentic workflow tool that operates against the full text of the corpus, identifying and reasoning across reactions, intermediates, structural relationships, and surrounding patent and commercial context in a single workflow.
Keep Reading
For most of the past three decades, the corporate IP team occupied a clear position near the end of the innovation process. Research and development explored a concept, leadership committed resources, scientists and engineers built the product, and only then did the work reach IP for protection, prosecution, and portfolio management. IP was a service function, expert and essential, but downstream of the decisions that mattered most. That sequence has quietly inverted. Today R&D comes to IP before resources are committed, asking what already exists in the patent record and treating the answer as a go or no-go signal on whether to pursue an idea at all. A prior art search is no longer just a legal precaution. It has become a strategic input that shapes which programs get funded, which get redirected, and which get killed before a dollar is spent.
This is a meaningful elevation of the IP team's role, and in most organizations it happened by default rather than by design. The mandate expanded because R&D became too expensive and too risky to pursue on instinct. The data and the tooling underneath the IP function, however, did not expand with it. The team is now being asked forward-looking strategic questions and is answering them with the one dataset it has always owned: the patent record. That mismatch between the question being asked and the data available to answer it is the source of a specific, costly, and underappreciated error. It has a name worth retiring from strategic vocabulary: the white space fallacy, the assumption that an empty region of the patent map is an open opportunity.
The stakes are higher than the tooling reflects
The reason this matters is that the decisions riding on these analyses are enormous, and the base rates for innovation are unforgiving. Failure rates across corporate R&D are persistently high. Industry research has long pegged new product failure somewhere between a third and half of all launches, and a substantial share of R&D projects never reach production at all. These failures have many causes, but a recurring and underexamined one is the practice of validating technical opportunity through patent analysis while leaving commercial opportunity unvalidated. A program clears the patent landscape, looks open, and proceeds, only to discover that the space was empty for reasons the patent record never showed. When the IP team's answer is steering investment direction, the cost of an incomplete map is no longer a missed filing. It is a misallocated research budget and a multi-year bet placed in the wrong direction.
White space and opportunity space are not the same thing
The cleanest way to see the error is to picture two overlapping circles. The first is patent white space, the regions of a technology landscape where few or no active patents exist. The second is commercial opportunity, the areas where genuine market demand and commercial momentum are forming. The portfolio every organization actually wants sits in the overlap, where a defensible technical position meets real commercial pull. That overlap is a narrow slice, and most teams cannot see it clearly because they are looking at only one of the two circles.
The reason patent white space gets mistaken for opportunity is structural rather than careless. Patent data is the dataset the IP team owns, the tool it has on hand, and the answer it can produce on demand. So the strategic question silently narrows from where should we invest to where is the patent map empty, and those two questions only sometimes have the same answer. The narrowing is invisible because it happens inside the framing of the analysis, not in its conclusions. Everyone in the room believes they are discussing opportunity. They are actually discussing patent density.
An empty region of the patent map can mean two very different things, and distinguishing between them is the whole game. It can be open for a reason, because there is no market demand, because the underlying science does not work yet, or because the unit economics never close. Easy to patent does not mean possible to monetize, and a clear space on the map can simply be a place no one has bothered to claim because there is nothing there worth claiming. Alternatively, the empty space can be a trap of the opposite kind, a region where competitors are very much active but moving through channels that never touch the patent system: trade secrets, defensive publications, or simply faster commercial execution that outruns the filing timeline. In both cases the patent map looks identical. It looks open. Only data drawn from outside the patent system can tell you which kind of empty you are actually looking at, and the two demand completely different strategic responses.
The inverse error is just as expensive and far less discussed. Some of the most contested, patent-dense regions of a landscape are exactly where the market is moving, and exactly where a given organization may be dangerously under-protected. A crowded patent map instinctively reads as a closed door, a market already won by incumbents. But density is a measure of competitive intensity, not of whether the opportunity is worth pursuing. Some of the most commercially urgent positions a company can take are in crowded spaces where the organization holds a real technical advantage but has under-filed relative to the competition. Reading crowdedness as a stop sign can forfeit exactly the positions most worth fighting for.
A patent is a twenty-year bet placed with rear-view data
Underneath the white space problem sits a deeper structural mismatch, this one about time. A patent is a roughly twenty-year commitment. That makes it one of the most forward-looking instruments a company holds, a claim staked on what will matter for two decades. Yet the patent record itself is one of the most backward-looking datasets available to anyone. Applications publish around eighteen months after they are filed, and the decisions behind them were made well before that. By the time a filing is visible in the public record, it describes a strategic choice that may be two or three years old. Patents are lagging indicators, sometimes by years, as applications crawl through prosecution. A team that validates a long-horizon investment using only existing patents is steering a twenty-year bet with a dataset that describes where the field was, not where it is going.
The question the IP team is increasingly asked to answer is whether a given portfolio or technology area will still matter in five to ten years. Answering that honestly requires three categories of signal that the patent record either omits entirely or reports too late to be useful.
The first is scientific momentum. Peer-reviewed papers, preprints, grant awards, and clinical activity reveal where the underlying technology is heading long before any of it reaches a patent application. Preprints in particular can surface a competitor's technical direction months to years ahead of the corresponding filing, because the science is published when it is done, not when the legal strategy is finalized. A field rich in recent publication but thin on filings is frequently an emerging opportunity, an early window in which an organization can establish a position before the patent landscape fills in and the easy ground is taken. To a patent-only view, that same field registers as white space and risks being dismissed as empty, when it is in fact the most valuable kind of crowded: crowded with science, not yet with claims.
The second is commercial signal. Venture funding, startup formation, mergers and acquisitions, corporate disclosures, and product launches reveal where commercial conviction is forming, frequently well ahead of patent activity. A technology domain showing minimal patent filings but hundreds of millions of dollars in aggregate venture funding is not white space. It is a market building momentum through channels that patent analytics simply cannot see. When an acquirer buys a startup, the strategic implication for every competitor in the space is immediate, but the patent assignment record may take months to update, and the commercial rationale for the deal, which market is being targeted, which product lines will expand, which competing approaches are being consolidated, never enters the patent data at all. That intelligence lives in deal records, regulatory filings, and corporate disclosures, in a layer of the landscape the patent-only team never sees.
The third is forward indicators, the signals that point at intent before it materializes as anything protectable. Regulatory filings, clinical pipelines, market intelligence, and hiring patterns all belong here. Hiring is among the most underused signals of all. The engineering and research roles a company is staffing frequently describe, in the job specifications themselves, exactly what the organization is building, and they appear long before any of that work surfaces as a filing. A competitor assembling a team around a specific technical capability is making a far earlier and often far clearer statement of direction than anything that will eventually reach a patent office.
None of this argues for abandoning patent data. Global patents remain the foundation, the authoritative record of what has actually been claimed and protected, and no serious analysis proceeds without them. The argument is narrower and harder to dismiss: patents are necessary but not sufficient for the strategic questions IP teams are now expected to answer. The foundation is solid. The problem is that three of the four walls are missing, and the team is being asked to assess the whole structure from the foundation alone.
Why the gap persists when it is so clearly understood
If the gap is this obvious, the fair question is why it endures across so many sophisticated organizations. The answer is mostly structural, not a failure of intelligence or diligence. Patent data is, for the typical IP team, the only native dataset it owns. It arrives through tools built for patent prosecution and portfolio management, instruments designed for IP attorneys running episodic, filing-driven workflows. Those tools are genuinely excellent at the job they were built to do. They were simply never built to answer strategic, forward-looking, commercially grounded questions, because those questions were not part of the IP team's mandate when the tools were designed.
The result is a quiet optimization toward the measurable. Teams optimize for the data they can see, and white space becomes the proxy for opportunity precisely because white space is the one thing the available tooling can actually measure. Scientific momentum, commercial conviction, and forward intent are harder to see not because they are less important but because they live in datasets the IP team's tools were never wired to ingest. The gap persists because closing it has historically meant stitching together multiple disconnected platforms by hand, a manual integration burden that most teams cannot sustain quarter after quarter. So the easier path wins, and the patent map stands in for the opportunity map by default.
Closing the gap, then, is not a matter of working harder inside the patent record. No amount of additional rigor applied to a patent-only dataset produces the signals that dataset does not contain. The fix is to put the other datasets on the same surface as the patent data, so that both circles can finally be examined together rather than one at a time, and so the overlap, the actual opportunity space, becomes visible rather than inferred.
Where this is heading
The platforms built for this problem treat patents, scientific literature, and commercial signals not as separate vendor silos to be reconciled by analysts but as a single intelligence substrate. Cypris was built specifically for this, an enterprise R&D intelligence platform that unifies more than 500 million patents and scientific papers alongside commercial and market signals, grounded in a proprietary R&D ontology and serving hundreds of enterprise customers and thousands of R&D and IP professionals across Fortune 500 companies. The application most relevant to the white space problem is exactly the overlap: surfacing the gaps between heavy patent activity and heavy publication activity, and the spaces where academic or commercial momentum is building but filings have not yet appeared. Those patterns are the opportunity space, and they are invisible inside any single-source tool by construction, because no single source contains both halves of the picture.
The more recent shift is from periodic analysis toward continuous intelligence. In June 2026 Cypris launched Agentic Monitoring, which runs continuously across patent offices, scientific literature, regulatory bodies, mergers and acquisitions, product launches, grant awards, and corporate news, delivering filtered and contextualized intelligence on a defined cadence rather than waiting for a quarterly manual rebuild. The significance is not the automation in itself. It is that the strategic questions reaching the IP team do not pause between reporting cycles. Competitors hire, raise, publish, and acquire continuously, and an intelligence model that refreshes once a quarter is structurally behind the landscape it is meant to describe. Continuous monitoring closes the timing gap on the same logic that integrated data closes the coverage gap.
The role of the corporate IP team has evolved into something genuinely strategic. The mandate, the data, and the tooling are only now beginning to catch up to it. The organizations that close that gap first will be the ones making forward decisions with a forward-looking map, while their competitors are still reading the rear-view mirror and calling it the road ahead.
FAQ
What is the difference between patent white space and commercial opportunity space?
Patent white space refers to regions of a technology landscape where few or no active patents exist. Commercial opportunity space refers to areas where genuine market demand and commercial momentum are forming. The two overlap only partially, and the highest-value IP portfolios sit in the intersection where a defensible technical position meets real commercial demand. Patent data alone cannot identify that intersection because it captures only one of the two dimensions, which is why empty patent regions are routinely mistaken for open opportunities.
What is the white space fallacy?
The white space fallacy is the assumption that an empty region of the patent map represents an open commercial opportunity. An absence of patents is a starting point for investigation, not a validated opportunity. A space can be empty because there is no market, because the underlying science does not yet work, or because competitors are operating outside the patent system through trade secrets, defensive publications, or faster commercial execution. Patent data cannot distinguish between these cases, and each one demands a completely different strategic response.
Why can patent data not answer strategic R&D questions on its own?
A patent is a roughly twenty-year commitment, which makes it a forward-looking instrument, while the patent record is a backward-looking dataset that publishes filings about eighteen months after submission and reflects decisions made earlier still. Patents are lagging indicators, sometimes by years. Answering whether a technology area will still matter in five to ten years requires scientific momentum, commercial signals, and forward indicators that the patent record either omits entirely or reports too late to act on.
Has the role of the corporate IP team actually changed?
Yes, and substantially. The IP team historically protected innovations after R&D produced them, sitting downstream of the decisions that mattered. Increasingly, R&D consults IP before committing resources and treats the resulting landscape analysis as a strategic go or no-go signal. The IP function has become a strategic decision input that shapes investment direction, even though the underlying data and tooling were originally built for patent prosecution and portfolio management rather than strategy.
What datasets do IP teams need beyond patents?
Three categories. Scientific literature, including papers, preprints, grants, and clinical activity, shows where technology is heading before filings appear. Commercial signals, including venture funding, startup formation, mergers and acquisitions, and product launches, show where commercial conviction is forming. Forward indicators, including regulatory filings, clinical pipelines, market intelligence, and hiring patterns, signal intent before it becomes protected IP. Patents remain the foundation, but these three categories supply the walls the foundation alone cannot.
Why does a field with many publications but few patents matter?
A technology area with extensive recent scientific publication but limited patent filings often represents an emerging opportunity, an early window in which an organization can establish an IP position before the landscape fills in. A patent-only view registers this same area as white space and may dismiss it as empty, missing the signal entirely. The space is not empty. It is crowded with science that has not yet converted into claims.
Can hiring patterns really indicate competitive activity?
Yes, and they are among the earliest signals available. The engineering and research roles a company staffs frequently describe, in the job specifications themselves, exactly what the company is building. Because hiring precedes filing by a considerable margin, a competitor's hiring activity can reveal technical direction months or years before any of that work surfaces in the patent record.
Why does a crowded patent area still matter strategically?
A patent-dense area instinctively reads as a closed market, but contested areas are often exactly where the market is moving and where an organization may be under-protected. Density signals competitive intensity, not the absence of opportunity. Treating a crowded map as a closed door can forfeit positions where a company holds a real technical advantage but has under-filed, which can be as costly an error as treating an empty map as an open opportunity.
Why does this gap persist if it is so well understood?
The gap is structural rather than a failure of judgment. Patent data is the only native dataset most IP teams own, accessed through tools built for prosecution and portfolio management. Teams optimize for the data they can see, so white space becomes a proxy for opportunity because it is the dimension the available tooling can actually measure. Historically, closing the gap meant manually stitching together disconnected platforms quarter after quarter, a burden most teams could not sustain, so the patent-only default persisted.
How are platforms addressing the patent-only limitation?
Purpose-built R&D intelligence platforms unify patents, scientific literature, and commercial signals into a single searchable substrate rather than separate tools requiring manual reconciliation. This allows teams to see the overlap between technical defensibility and commercial momentum directly rather than inferring it. The emerging direction is continuous monitoring across patents, literature, regulatory activity, mergers and acquisitions, and corporate news, replacing periodic manual analysis with always-on intelligence that keeps pace with a landscape that never stops moving.
Sustainable aviation fuel has moved from pilot projects to a mandated market, and its patent landscape is distinctive because SAF is not a single technology but a set of competing production routes, each with its own feedstocks, catalysts, and process chemistry. Peer-reviewed technical reviews lay out the route taxonomy: the hydroprocessed-ester-and-fatty-acid route converts waste oils and fats into jet fuel and is currently the most mature; the Fischer-Tropsch route gasifies biomass or waste into synthesis gas and rebuilds it into hydrocarbons; the alcohol-to-jet route converts ethanol or other alcohols into jet-range molecules; and the synthetic power-to-liquid route, including methanol-mediated pathways, combines captured carbon dioxide with green hydrogen to make e-fuels with no biological feedstock at all.¹,²,³,⁴,⁷ Because each route is a distinct region of patenting, freedom-to-operate and white space analysis must treat SAF as several landscapes at once, spanning feedstock pretreatment, catalysts, conversion processes, and upgrading.
The landscape is being pulled forward by regulation more directly than most. Under the European Union's ReFuelEU Aviation regulation, the sustainable share of aviation fuel supplied at EU airports rises stepwise to 70 percent by 2050, with a dedicated sub-obligation for synthetic e-fuels and an anti-tankering rule requiring airlines to uplift most of their fuel where they operate; Switzerland adopted the ReFuelEU framework from January 1, 2026.⁹ This creates both a deadline and a guaranteed market against a very large baseline, since global commercial jet-fuel demand is on the order of 100 billion gallons a year and is projected to rise substantially by 2050.¹ The near-term response has concentrated in the waste-oil route because it is the most mature,⁴,⁵ but the mandates specifically favor synthetic e-fuels in the longer term, which is steering research and filings toward the power-to-liquid route and its underlying carbon-conversion and catalysis challenges. The patent record shows this tension clearly: across the Cypris corpus of more than 500 million patents and scientific papers, the SAF space holds roughly 6,000 de-duplicated families and grew about 3.6 times between 2022 and 2024, and on an indicative basis the Fischer-Tropsch and e-fuel routes lead patent activity, ahead of hydroprocessed waste oils, with alcohol-to-jet the smallest slice, even though the waste-oil route currently leads in deployed production capacity, a divergence between where filing and where building are concentrated. The most active assignees span engine makers, refining-and-catalysis licensors, and route pure-plays, and the United States leads on geography, followed by the United Kingdom, China, France, and the Nordic producers. Because applications publish about eighteen months after filing, the most recent catalyst and e-fuel filings are under-represented (2025 and 2026 counts are partial), so the current frontier is more active than granted-patent counts suggest.
The strategic question is which route and layer to back, and the white space sits where cost and feedstock constraints are hardest. The waste-oil route is limited by feedstock availability, so its white space is narrower; the Fischer-Tropsch and alcohol-to-jet routes turn on catalyst performance and process integration;²,³,⁸ and the synthetic e-fuel route, though earliest and most expensive, is the one the mandates most favor and the one with the most open, high-value IP, particularly in the catalysts and process designs that lower the cost of converting carbon dioxide and hydrogen into jet fuel.⁶,⁷ Reading the landscape by route, feedstock, catalyst, and process, and tracking both the patents and the underlying chemistry research, is what separates a crowded region from an open one.
Where the SAF white space is
Synthetic e-fuel catalysis. Catalysts and process designs that lower the cost of converting captured carbon dioxide and green hydrogen into jet-range hydrocarbons are the most favored by mandate and among the most open, high-value targets.⁶,⁷
Alcohol-to-jet conversion. Improved catalysts and process integration for converting alcohols to jet-range molecules are an active, still-developing route.⁸
Fischer-Tropsch from waste and biomass. Gasification, syngas conditioning, and Fischer-Tropsch catalysis for waste and biomass feedstocks are a distinct, contested layer.²,³
Feedstock flexibility and pretreatment. Technologies that broaden or pretreat feedstocks, easing the supply constraint on mature routes, are a differentiated area.⁴
Process intensification and integration. Designs that integrate steps, cut energy use, and lower capital cost are where scale-up economics are decided.⁵
How AI-powered landscape and white space analysis helps
Resolving a landscape that spans several production routes, each with its own feedstocks, catalysts, and processes, under a moving regulatory timeline, requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by route, feedstock, catalyst, and process across varied terminology, attribution that normalizes filers to canonical entities and tracks new entrants, and continuous monitoring that keeps pace with a mandate-driven surge. Because SAF advances appear in scientific and catalysis literature before they are patented, reading both patents and literature gives the earliest signal of where scalable routes are emerging.
Where Cypris fits
Cypris runs patent landscape and white space analysis for multi-route fields such as sustainable aviation fuel across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by production route, waste-oil, Fischer-Tropsch, alcohol-to-jet, and synthetic e-fuel, and by layer, feedstock, catalyst, conversion, and upgrading, and normalizes filers to canonical entities, so a team can resolve which routes and layers are crowded and which remain open as white space, and can track new entrants as the field scales. Semantic search across patents and scientific literature connects filings to the underlying catalysis and process research, which is where SAF advances appear first. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined route over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
What is the sustainable aviation fuel patent landscape? The sustainable aviation fuel patent landscape is the set of patents covering the several routes used to make jet fuel with lower lifecycle emissions, including hydroprocessed waste oils, Fischer-Tropsch fuels, alcohol-to-jet, and synthetic power-to-liquid e-fuels. Each route has distinct feedstocks, catalysts, and processes. It is best understood as several landscapes rather than one.
Why is regulation shaping SAF patenting? Regulation shapes SAF patenting because binding blending mandates require a rising share of sustainable aviation fuel over the coming decades, reaching 70 percent by 2050 under the EU ReFuelEU Aviation regulation, with a dedicated sub-mandate for synthetic e-fuels. Near-term activity has concentrated in the mature waste-oil route, while the mandates steer longer-term research toward e-fuels. The patent record tracks this policy pull closely.
What production routes does the SAF landscape cover? The SAF landscape covers hydroprocessed waste oils and fats, Fischer-Tropsch fuels from gasified biomass or waste, alcohol-to-jet conversion, and synthetic power-to-liquid e-fuels made from captured carbon dioxide and green hydrogen. Each is a distinct region of patenting. Freedom-to-operate and white space analysis must treat them separately.
Where is the white space in SAF? The white space sits in synthetic e-fuel catalysis, alcohol-to-jet conversion, Fischer-Tropsch from waste and biomass, feedstock flexibility and pretreatment, and process intensification. The mature waste-oil route is comparatively crowded and feedstock-limited. The most open, high-value opportunities are in the e-fuel catalysts and processes the mandates most favor.
Why is the synthetic e-fuel route strategically important? The synthetic e-fuel route is strategically important because the mandates specifically favor it in the longer term, it has no biological feedstock limit, and it is the least mature and most expensive route, which leaves the most open, high-value IP. The central challenge is lowering the cost of converting carbon dioxide and hydrogen into jet fuel. That is where much of the defensible catalysis and process IP is concentrating.
Why does the patent record differ from deployed capacity in SAF? The patent record differs from deployed capacity because filing tends to run ahead of building. In the Cypris corpus the Fischer-Tropsch and e-fuel routes lead in patent activity, even though the hydroprocessed waste-oil route currently leads in installed production capacity. That divergence signals where developers expect the next phase of growth.
What software helps analyze the sustainable aviation fuel patent landscape? Software for the SAF landscape should cluster activity by production route and process layer, resolve filers to canonical owners, search patents and scientific literature semantically, and monitor a mandate-driven field continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.
Which teams use SAF patent landscape analysis? SAF patent landscape analysis is used by R&D, innovation, IP, and strategy teams at fuel producers, chemicals and catalysis companies, airlines and energy majors, and their partners, as well as investors and policymakers. It informs which route to back, where to file, and where competitors are concentrated. Cypris serves hundreds of enterprise customers across chemicals, energy, advanced materials, and other regulated industries.
Endnotes
- Heyne, J., Holladay, J., & Abdullah, Z. (2020). Sustainable aviation fuel: review of technical pathways. Pacific Northwest National Laboratory / U.S. Department of Energy, Bioenergy Technologies Office. https://doi.org/10.2172/1660415
- Zhang, X., Zheng, Y., Li, J., & Wang, X. (2025). Research advances and future perspectives in Fischer-Tropsch synthesis for sustainable aviation fuel. Sustainable Energy & Fuels. https://doi.org/10.1039/d5se01412c
- Vreugdenhil, B., Boymans, E., Viar, H., et al. (2025). Syngas to sustainable aviation fuel: emerging catalysts and routes. Applied Catalysis A: General. https://doi.org/10.1016/j.apcata.2025.120554
- Chang, K., Ng, J., Japar, W. M. A. W., et al. (2026). Lipid feedstocks for sustainable aviation fuel via HEFA: status and challenges. Renewable and Sustainable Energy Reviews. https://doi.org/10.1016/j.rser.2026.117006
- Gómez, J., & Gyandoh, D. (2025). Techno-economic analysis of HEFA and lignocellulosic biomass conversion for sustainable aviation fuel. Applied Energy. https://doi.org/10.1016/j.apenergy.2025.126421
- Riaz, A., Qyyum, M. A., Al-Muhtaseb, A. H., Al-Jahwari, F., & Saeed, A. (2026). Carbon-derived and biomass-based sustainable aviation fuel pathways: a comparative techno-economic and life-cycle review for aviation decarbonization. Carbon Capture Science & Technology. https://doi.org/10.1016/j.ccst.2026.100641
- Karlsruhe Institute of Technology (2025). Sustainable aviation fuel production via the methanol pathway: a technical review. Sustainable Energy & Fuels. https://doi.org/10.5445/ir/1000187428
- Probabilistic technoeconomic analysis of alcohol-to-jet sustainable aviation fuel: implications for design and decision making (2026). https://doi.org/10.1088/2977-3504/ae7801/v2/review1
- European Commission, Directorate-General for Mobility and Transport. ReFuelEU Aviation. https://transport.ec.europa.eu/transport-modes/air/environment/refueleu-aviation_en
Cellular reprogramming has become one of the most closely watched areas in longevity biotechnology, and its patent landscape is distinctive because the leading approach builds directly on an already foundational technology. Full reprogramming, using the four Yamanaka factors, resets an adult cell all the way to a pluripotent, embryonic-like state; partial or transient reprogramming instead applies a subset of those factors briefly, aiming to roll back the epigenetic state of an aged cell toward a younger profile while preserving its identity and function. In animal models, partial reprogramming has ameliorated age-associated hallmarks and, in one landmark study, restored youthful epigenetic patterns and recovered vision after optic-nerve injury, evidence that framed aging partly as a loss of epigenetic information that reprogramming can help reverse.¹,² Because a rejuvenation therapy is assembled from several independently patentable pieces, the reprogramming-factor set and its ratios, the delivery system, the inducible control mechanism, the target tissue and indication, and the tools used to measure biological age, freedom-to-operate is a multi-layer, multi-owner analysis rather than a single clearance.
The foundational layer shapes everything above it. The original induced-pluripotent-stem-cell reprogramming methods, established through the forced expression of a defined set of transcription factors, sit under a well-known foundational estate that has been broadly licensed,³ and partial-reprogramming approaches inherit questions about how far that foundation reaches. Independent work has shown that epigenetic reprogramming can unlock tissue regenerative potential, reinforcing why these methods are so contested.⁴ This academic origin is visible in the ownership record: across the Cypris corpus of more than 500 million patents and scientific papers, the most active assignees in the cellular-reprogramming and induced-pluripotency space are led by academic and translational institutions, including Kyoto University, the University of California San Diego, the University of Texas System, Memorial Sloan Kettering, and Harvard, alongside cell-therapy companies, and the corpus holds on the order of 28,700 de-duplicated families, with the United States, China, and Japan the leading jurisdictions. Layered on top are newer, fast-growing estates specific to partial and transient reprogramming, cyclic and inducible expression schemes, chemical or small-molecule reprogramming that avoids transcription factors altogether, and tissue-specific delivery. Because applications publish about eighteen months after filing, the most recent reprogramming, delivery, and control filings are under-represented, so the current frontier is more active than granted-patent counts suggest.
The landscape is a well-capitalized race, and the strategic question is which layer to own. In January 2026 the field reached a milestone when the US Food and Drug Administration cleared the first human trial of a partial epigenetic reprogramming therapy, an investigational optic-neuropathy treatment; the clearance authorizes a first-in-human study and is not itself evidence of efficacy.⁹ Across the Cypris corpus, filings in this space grew from a few hundred families per year at the start of the last decade to roughly 3,200 in 2024, with 2025 counts partial because of the publication lag. Several richly funded companies are pursuing different factor sets, delivery routes, and target tissues, and a recurring challenge is to separate genuine rejuvenation, a measured reduction in biological age, from a mere slowing of decline.⁵ The durable value increasingly sits not in the general idea of reprogramming, which rests on the contested foundation, but in the specific, well-supported improvements: safe and controllable expression systems that avoid tumor risk, factor combinations and chemical alternatives, tissue-targeted delivery, and the validated biomarkers, including epigenetic clocks, used to demonstrate rejuvenation.⁶,⁷,⁸ Reading the landscape by layer and by owner, and tracking both the patents and the underlying research, is what separates a workable position from a blocked one.
What creates FTO risk in cellular reprogramming
Foundational reprogramming claims. These cover the underlying induced-pluripotency methods and factor sets, a broadly licensed foundation whose reach into partial approaches shapes everything above it.
Partial and inducible-control claims. These cover transient, cyclic, and inducible expression schemes that rejuvenate without full dedifferentiation, a fast-growing and contested layer.
Delivery claims. These cover viral vectors, lipid nanoparticles, and mRNA delivery of reprogramming factors, a distinct and separately owned layer often decisive for a therapy.
Chemical and small-molecule reprogramming claims. These cover approaches that induce rejuvenation without transcription factors, an emerging and less-crowded route.
Target, indication, and biomarker claims. These cover specific tissues and indications and the epigenetic-age measurements used to demonstrate effect, so a platform can be free for one application and blocked for another.
How AI-powered landscape and FTO analysis helps
A multi-layer, multi-owner landscape built on a contested foundation is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant foundational, partial-reprogramming, delivery, control, and target claims regardless of terminology, attribution that resolves academic and commercial owners to canonical entities and captures the license and spinout chains, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and the fast-moving research. Because reprogramming advances appear in scientific literature well before they are patented, reading both patents and literature gives the earliest warning of where the field is heading.
Where Cypris fits
Cypris runs patent landscape and freedom-to-operate analysis for multi-layer, academically rooted fields such as cellular reprogramming across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, foundational reprogramming, partial and inducible control, delivery, chemical reprogramming, and target and biomarker, and normalizes academic and commercial owners to canonical entities, so a team can trace how rights and licenses are distributed across many parties rather than read a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where new factor sets, control systems, and delivery methods emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
What is cellular reprogramming in the longevity context? Cellular reprogramming in the longevity context is the use of reprogramming factors to reset the epigenetic state of aged cells toward a younger profile. Partial or transient reprogramming applies a subset of the Yamanaka factors briefly, aiming to rejuvenate cells without erasing their identity. It is being pursued as an approach to age-related disease and tissue restoration.
Why is freedom-to-operate hard for reprogramming therapies? Freedom-to-operate is hard for reprogramming therapies because a therapy is assembled from several independently patentable layers, the reprogramming-factor set, the delivery system, the inducible control mechanism, the target tissue, and biomarker tools, often held by different owners on top of a foundational estate. Clearing one layer does not clear the others. FTO is therefore a multi-layer, multi-owner analysis.
How does the foundational iPSC estate affect partial reprogramming? The foundational induced-pluripotent-stem-cell estate affects partial reprogramming because partial approaches use the same reprogramming factors, so questions about how far the foundation reaches propagate into the newer methods. The foundation has been broadly licensed. Partial-reprogramming developers must consider both the foundation and the specific improvement layers.
What claim types create FTO risk in reprogramming? Five claim types create FTO risk: foundational reprogramming claims, partial and inducible-control claims, delivery claims, chemical and small-molecule reprogramming claims, and target, indication, and biomarker claims. Each covers a distinct layer and can be held by a different owner. Control systems and delivery are especially decisive.
Where is the white space in cellular reprogramming? The white space sits in safe and controllable expression systems that avoid tumor risk, chemical and small-molecule reprogramming, tissue-specific delivery, specific factor combinations, and validated biomarkers of biological age. The general concept rests on a contested foundation. The durable, defensible value is in these specific improvement and delivery layers.
Why does reprogramming analysis need scientific literature? Reprogramming analysis needs scientific literature because new factor sets, control systems, and delivery methods appear in research well before they are patented, so the literature gives the earliest signal in a fast-moving field. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.
What software helps analyze the cellular reprogramming patent landscape? Software for the cellular reprogramming landscape should resolve academic and commercial owners and license chains to canonical entities, cluster the foundational, control, delivery, and target layers, search patents and scientific literature semantically, and monitor a fast-moving field continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.
Which teams need reprogramming patent landscape and FTO analysis? Reprogramming patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at longevity and gene-therapy companies, academic technology-transfer offices, and investors assessing rejuvenation assets. The multi-layer, contested landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.
This article addresses patents and freedom-to-operate and is not legal, medical, or investment advice, and contains no clinical or dosing guidance. FTO determinations should be reviewed with qualified patent counsel.
Endnotes
- Ocampo, A., Reddy, P., Izpisua Belmonte, J. C., et al. (2016). In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell, 167(7). https://doi.org/10.1016/j.cell.2016.11.052
- Lu, Y., Krishnan, A., Sinclair, D. A., et al. (2020). Reprogramming to recover youthful epigenetic information and restore vision. Nature, 588. https://doi.org/10.1038/s41586-020-2975-4
- Takahashi, K., & Yamanaka, S. (2013). Induced pluripotent stem cells in medicine and biology. Development, 140(12). https://doi.org/10.1242/dev.092551
- Reddy, P., Izpisua Belmonte, J. C., & Memczak, S. (2021). Unlocking tissue regenerative potential by epigenetic reprogramming. Cell Stem Cell, 28(3). https://doi.org/10.1016/j.stem.2020.12.006
- Zhang, B., Trapp, A., Kerepesi, C., & Gladyshev, V. N. (2021). Emerging rejuvenation strategies—reducing the biological age. Aging Cell, 21(1). https://doi.org/10.1111/acel.13538
- Moqri, M., Poganik, J. R., Gladyshev, V. N., & Horvath, S. (2025). What makes biological age epigenetic clocks tick. Nature Aging. https://doi.org/10.1038/s43587-025-00833-1
- Mammalian Methylation Consortium; Horvath, S., et al. (2023). Universal DNA methylation age across mammalian tissues. Nature Aging, 3. https://doi.org/10.1038/s43587-023-00462-6
- Ferrucci, L., et al. (2019). Measuring biological aging in humans: a quest. Aging Cell, 19(2). https://doi.org/10.1111/acel.13080
- Life Biosciences (2026, January 28). Life Biosciences announces FDA clearance of IND application for ER-100 in optic neuropathies. https://www.lifebiosciences.com/life-biosciences-announces-fda-clearance-of-ind-application-for-er-100-in-optic-neuropathies